Near to our results, Sebestyen et al.  verified that mTOR activity was presented among DLBCL patients in 62% of the studied population, by positive immunostaining for p-S6 the most sensitive marker of mTOR activity [49]. Also, Schedel et al., examined the expression of mTOR and its phosphorylated (active) counterpart found [50]. The results suggested that mTOR is highly active in different cancer types, as various permanent cell lines of bladder cancer and head & neck squamous cell carcinoma. This evidence concerns the gene MTOR and urinary bladder carcinoma.